全球异种移植市场 – 2029 年行业趋势及预测

市场分析和规模

移植是治疗终末期器官衰竭的一种成功方法。但人体器官供需不平衡是临床移植的瓶颈。根据美国政府器官捐赠和移植信息，截至 2019 年 1 月，美国有超过 113,000 人处于移植等候名单上，而 2018 年仅进行了 36,528 例移植手术。

Data Bridge Market Research 分析，异种移植市场规模在 2021 年为 129.5 亿美元，到 2029 年将飙升至 245.1 亿美元，预计在 2022 年至 2029 年的预测期内复合年增长率为 8.30%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

Any procedure that involves the transplantation, implantation, or infusion into a human recipient of either live nonhuman animal cells, tissues, or organs, or human body fluids, cells, tissues, or organs that have had ex vivo contact with live nonhuman animal cells, tissues, or organs, is referred to as xenotransplantation. The demand for human organs for clinical transplantation significantly outnumbers the availability, which has fueled the development of xenotransplantation.

Xenotransplantation Market Dynamics

Drivers

• Rise in surgeries

In the forecast period of 2022-2029, the rising volume of organ transplantation surgeries, rising occurrences of chronic diseases, rising investment for the development of advanced and technical products, and the growing number of geriatric population are some of the factors that will likely boost the growth of the xenotransplantation market. Changing lifestyles among the rising population, on the other hand, would enhance numerous opportunities, resulting in the rise of the xenotransplantation market throughout the forecast period.

• Increasing demand for tissue and organ transplantation

Organ failure can be caused by a variety of things, including minor trauma, blood loss, poisoning, and drug usage. The rising prevalence of kidney disease, excessive alcohol intake, and a poor diet have all contributed to the expansion of the Organ Transplantation industry. Chronic sickness and organ failure affect a large portion of the population.

• Improved understanding of immune system

One of the success stories of the second half of the twentieth century is organ transplantation. Indeed, it is its success, which has resulted in the referral of ever-increasing numbers of patients, that has caused a shortage of donor organs. Our improved understanding of the immune system and the immune rejection process has led to the development of therapies that, hopefully, will overcome the robust immune responses associated with xenogeneic tissue transplantation. Human clinical trials utilising animal cells and organs to treat some of these diseases are expected to become a reality in the coming years.

Opportunities

• Xenotransplantation could still be beneficial without long-term success

Even though xenotransplantation research has so far yielded mixed results in terms of extending life, allowing people who are waiting for organs to utilise animal organs could help them survive longer until they can obtain human organs. It will keep the black market at bay. Although it is dangerous to sell human organs on the illicit market, some people consider it as a last resort when they are desperate to preserve their lives. The use of animal organs as a substitute could help to minimise this exploitative trade, which is extremely dangerous because the quality and condition of the organs, as well as how they were obtained, are unknown.

Restraints/Challenges

Treatment of failure is helping to develop the market, as is technological innovation and an increase in the number of issuing banks. Globally, there is a surge in demand for organ replacement, particularly kidney, heart, and liver transplants. The market is hampered by the high cost of transplantation, which includes the high cost of completed services, the restricted number of donors accessible, and the number of failures that occur. Patients are becoming more concerned as the prevalence of organ failure rises. The shortage of resources available on the market is one of the issues.

This xenotransplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the xenotransplantation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 Impact on Xenotransplantation Market

Many people who would benefit from organ transplantation are unable to do so because human organ donation is insufficient to meet medical demands. Xenotransplantation has the potential to provide infinite access to pig organs for transplantation, and pig-to-non-human primate models have shown promising results that could soon lead to clinical trials. However, one of the specific ethical issues of xenotransplantation is that the risk of spreading zoonotic disease into the community must be evaluated against the patient's benefit. While most specialists feel that zoonosis can be controlled, many people who are hesitant or opposed to clinical xenotransplantation are concerned about disease transfer from animal donors to human recipients. The COVID-19 pandemic represents a scenario (fast global spread of a highly contagious novel zoonotic disease with no natural human defence) that would appear to warrant concern, particularly in the United States, which has mostly evaded prior pandemic outbreaks. However, there are numerous variations between zoonosis found in the wild and zoonosis acquired during xenotransplantation that favour the latter's safety. Outside of the field, however, these distinctions, as well as the advantages of xenotransplantation, are not well appreciated. As a result, we must consider the impact of the COVID-19 epidemic on attitudes regarding xenotransplantation.

Global Xenotransplantation Market Scope

The xenotransplantation market is segmented on the basis of product type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Organ Preservation Solutions
•  Transplant Diagnostics
• Tissue Products
   

Applications

• Heart
•  Kidney
•  Other Organs

Xenotransplantation Market Regional Analysis/Insights

The xenotransplantation market is analysed and market size insights and trends are provided by country, product type and application as referenced above.

The countries covered in the xenotransplantation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominating the xenotransplantation market due to the growing development in the medical sector along with increasing cases of organ failure.

由于人口不断增长以及各种市场制造商的普及，预计亚太地区将在 2022 年至 2029 年的预测期内以最高的增长率增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和异种移植 市场份额分析

异种移植市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对异种移植市场的关注有关。

异种移植市场的一些主要参与者包括：

• Terumo Medical Corporation（日本）
• Transonic（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• 安斯泰来制药株式会社 (日本)
• Preservation Solutions, Inc.（美国）
• OrganOX Limited（英国）
• Bio Med Pvt. Ltd.（美国）
• 移植生物医学（西班牙）
• TransMedic 私人有限公司 (新加坡)
• 诺华公司（瑞士）
• 器官恢复系统（美国）
• Accord Healthcare（美国）
• 辉瑞公司（美国）
• Veloxis Pharmaceuticals, Inc.（美国）

SKU-53139